DVL1 Gene

📖 Wiki Page

gene1108 wordssynced 2026-04-02

DVL1 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DVL1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DVL1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>DVL1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=DVL1" target="_blank">Search NCBI</a></td>
</tr>
</table>

DVL1 (Dishevelled Segment Polarity Protein 1) is a key cytoplasmic effector of the Wnt signaling pathway that plays critical roles in embryonic development, neuronal differentiation, synapse formation, and adult brain function. As a central component of both canonical (β-catenin-dependent) and non-canonical Wnt pathways, DVL1 integrates extracellular Wnt signals to regulate gene transcription, cytoskeletal dynamics, and cell-cell communication. Mutations in DVL1 cause Robinow syndrome, an autosomal dominant disorder characterized by mesomelic limb shortening, genital hypoplasia, and distinctive facial features. Additionally, dysregulated DVL1 signaling has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [autism spectrum disorders](/diseases/autism-spectrum-disorder) [1][2].

--- [@macdonald2009]
title: DVL1 Gene [@schwarzromond2007]

--- [@clevers2012]

...

DVL1 Gene

Introduction

--- [@macdonald2009]
title: DVL1 Gene [@schwarzromond2007]

--- [@clevers2012]

.infobox.infix-gene [@avila2020]
; Gene Symbol [@white2015]
: DVL1 [@liu2018]
; Full Name [@inestrosa2014]
: Dishevelled Segment Polarity Protein 1 [@cardozo2009]
; Chromosomal Location [@mineur2017]
: 1p36.33 [@zhang2019]
; NCBI Gene ID
: [1855](https://www.ncbi.nlm.nih.gov/gene/1855)
; OMIM
: [604360](https://www.omim.org/entry/604360)
; Ensembl ID
: [ENSG00000107485](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107485)
; UniProt ID
: [Q92997](https://www.uniprot.org/uniprotkb/Q92997)
; Associated Diseases
: Alzheimer's Disease, Autism Spectrum Disorder, Robinow Syndrome

Overview

Mermaid diagram (expand to render)

DVL1 encodes a member of the Dishevelled (DVL) protein family, which are key components of the Wnt signaling pathway. DVL1 acts as a positive regulator of canonical Wnt signaling by antagonizing beta-catenin degradation. In [neurons](/entities/neurons), DVL1 localizes to synapses and regulates synaptic formation and function. DVL1 mutations cause Robinow syndrome, an autosomal dominant genetic disorder. Dysregulated DVL1 signaling has been implicated in Alzheimer's disease and autism spectrum disorders.

Protein Structure and Domains

The DVL1 protein contains several conserved domains that mediate protein-protein interactions and signal transduction:

N-Terminal DIX Domain (Axin/Dishevelled Domain)

The DIX domain (approximately 80 amino acids) mediates DVL1 self-association and polymerization, which is essential for signal transduction. This domain allows DVL1 to form cytoplasmic puncta in response to Wnt stimulation [3].

PDZ Domain

The PDZ domain (approximately 90 amino acids) binds to the C-terminal motif of transmembrane receptors and scaffolding proteins, including:

Frizzled (Fz) receptors
Van Gogh (Vangl) proteins
Axin
Nedu

DEP Domain (Dishevelled, Egl-27, and Plexin)

The DEP domain (approximately 80 amino acids) is required for:

Membrane localization of DVL1
Activation of non-canonical Wnt pathways (planar cell polarity)
Interaction with downstream effectors

C-Terminal Proline-Rich Region

This region contains binding sites for SH3 domain-containing proteins and participates in cytoskeletal regulation.

Molecular Functions

Canonical Wnt/β-Catenin Signaling

In the canonical Wnt pathway, DVL1 acts downstream of Frizzled receptors to inhibit the β-catenin destruction complex (containing GSK3β, APC, Axin, and CK1α). Upon Wnt ligand binding:

DVL1 is recruited to the plasma membrane via interaction with Frizzled receptors

DVL1 polymerizes and sequesters Axin away from the destruction complex

β-Catenin accumulates and translocates to the nucleus

β-Catenin co-activates TCF/LEF transcription factors to express Wnt target genes [4]

Non-Canonical Wnt Signaling

DVL1 also participates in β-catenin-independent pathways:

Planar Cell Polarity (PCP) Pathway

DVL1 regulates cytoskeletal organization via interaction with Daam1, Rac1, and RhoA
Controls cell polarity and migration during neural tube formation
Regulates dendritic arborization in neurons

Wnt/Ca²⁺ Pathway

DVL1 can activate phospholipase C (PLC) and increase intracellular calcium
Regulates calcium-dependent signaling in neurons

Synaptic Function

DVL1 localizes to both pre- and post-synaptic compartments where it:

Regulates dendritic spine formation and morphology
Controls synaptic assembly via interaction with PSD-95
Modulates synaptic plasticity and [long-term potentiation](/mechanisms/long-term-potentiation) (LTP)
Participates in [NMDA](/entities/nmda-receptor) receptor trafficking [5]

Expression Pattern

DVL1 is widely expressed in the developing and adult brain:

Developmental Expression

High expression during embryonic neurogenesis
Expressed in neural progenitor cells
Critical for cortical plate formation

Adult Brain Expression

Cerebral [cortex](/brain-regions/cortex): pyramidal neurons in layers II-VI
[Hippocampus](/brain-regions/hippocampus): CA1-CA3 pyramidal cells, dentate gyrus granule cells
Cerebellum: Purkinje cells and granule cells
Subventricular zone: neural stem cells
Synapses: both pre-synaptic terminals and post-synaptic densities

Disease Associations

Robinow Syndrome

Heterozygous missense mutations in DVL1 cause autosomal dominant Robinow syndrome, characterized by:

Mesomelic limb shortening (short forearms and lower legs)
Genital hypoplasia (hypoplastic genitalia)
Distinctive facial features (broad nasal bridge, midface retrusion)
Normal intelligence in most cases
Occasional vertebral segmentation defects [6][7]

The pathogenic mechanisms involve:

Dominant-negative effects on Wnt signaling
Impaired DVL1 polymerization
Dysregulated transcription of Wnt target genes during embryogenesis

Alzheimer's Disease

Multiple lines of evidence link DVL1 to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis:

[Amyloid-Beta](/proteins/amyloid-beta) (Aβ) Regulation

Wnt signaling is neuroprotective against Aβ toxicity
DVL1 expression is altered in AD brains and AD mouse models
Aβ oligomers disrupt Wnt signaling by affecting DVL1 localization

[Tau](/proteins/tau) Pathology

GSK3β, a key kinase in Wnt signaling, phosphorylates [tau](/proteins/tau)
DVL1 dysfunction may contribute to tau hyperphosphorylation
Wnt pathway activation reduces tau pathology in experimental models

Synaptic Dysfunction

DVL1 is critical for synaptic plasticity
Wnt pathway deficits contribute to synaptic loss in AD
DVL1-mediated spine changes are impaired in AD [8]

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease):

Wnt/DVL signaling is dysregulated in the substantia nigra
Dopaminergic neurons are particularly vulnerable to Wnt pathway disruption
[LRRK2](/entities/lrrk2) (a PD gene product) interacts with DVL1
DVL1 dysfunction may contribute to [α-synuclein](/proteins/alpha-synuclein) toxicity [9]

Autism Spectrum Disorder

DVL1 is implicated in [autism spectrum disorders](/diseases/autism-spectrum-disorder) through:

Synaptic function regulation
Dendritic spine morphology
Social behavior and cognitive flexibility
Interaction with autism-related genes (NRXN1, CNTNAP2) [10]

Cancer

While not a neurodegenerative disease, DVL1 dysregulation is observed in various cancers:

DVL1 overexpression in colorectal, breast, and lung cancers
Role in tumor cell proliferation and invasion
Potential therapeutic target

Therapeutic Implications

Drug Development

Targeting DVL1 and the Wnt pathway for neurodegeneration:

Wnt pathway activators: Small molecules that enhance DVL1 function
GSK3β inhibitors: Downstream targets that reduce tau phosphorylation
Wnt-derived peptides: Mimic Wnt signaling for therapeutic benefit
Frizzled agonists: Activate upstream of DVL1 [11]

Biomarkers

DVL1 expression changes may serve as:

Indicators of Wnt pathway dysfunction in neurodegenerative diseases
Markers of synaptic integrity
Therapeutic response biomarkers

Research Directions

Ongoing research focuses on:

Understanding DVL1 mutations in Robinow syndrome
Elucidating DVL1 functions in specific neuronal subtypes
Developing Wnt pathway-targeted therapeutics for AD and PD
Characterizing DVL1 interactions with disease-related proteins
Single-cell analysis of DVL1 expression in neurodegeneration

Background

The study of Dvl1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Pathway Diagram

The following diagram shows the key molecular relationships involving DVL1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

DVL1 Gene

DVL1 Gene

Introduction

DVL1 Gene

Introduction

Overview

Protein Structure and Domains

N-Terminal DIX Domain (Axin/Dishevelled Domain)

PDZ Domain

DEP Domain (Dishevelled, Egl-27, and Plexin)

C-Terminal Proline-Rich Region

Molecular Functions

Canonical Wnt/β-Catenin Signaling

Non-Canonical Wnt Signaling

Synaptic Function

Expression Pattern

Disease Associations

Robinow Syndrome

Alzheimer's Disease

Parkinson's Disease

Autism Spectrum Disorder

Cancer

Therapeutic Implications

Drug Development

Biomarkers

Research Directions

Background

See Also

Pathway Diagram